Related by context. All words. (Click for frequent words.) 72 mitoxantrone plus 72 leukemia APL 71 refractory acute myeloid 68 refractory acute promyelocytic 68 refractory CLL 68 leukemia AML 68 refractory CTCL 68 relapsing remitting MS RRMS 68 refractory colorectal cancer 67 refractory chronic lymphocytic 67 relapsed refractory multiple myeloma 67 refractory indolent non 67 refractory multiple myeloma 67 leukemia CLL 67 relapsed MM 67 refractory AML 67 prostate cancer HRPC 67 recurrent glioblastoma multiforme 66 ® lenalidomide 66 refractory cutaneous T 66 Myelodysplastic Syndrome MDS 66 relapsed leukemia 66 tumors GIST 66 malignant ascites 66 de novo kidney transplant 66 hormone refractory metastatic prostate 66 refractory NSCLC 66 acute mania 66 systemic ALCL 66 Vincristine 66 anthracycline taxane 66 relapsed ovarian cancer 65 metastatic malignant 65 systemic anaplastic large 65 taxane chemotherapy administered 65 Torisel temsirolimus 65 Annamycin 65 basiliximab 65 Refractory Hodgkin Lymphoma 65 recurrent glioblastoma 65 recurrent malignant glioma 65 non splenectomized 65 refractory DLBCL 65 metastatic GIST 65 biliary tract cancer 65 Bayer Nexavar 65 refractory lymphoma 65 cyclophosphamide methotrexate 65 adriamycin 65 CYT# potent vascular disrupting 65 underwent liver transplantation 64 Peginterferon alfa 2b 64 chemotherapy cisplatin 64 paclitaxel Taxol R 64 metastatic colorectal 64 anthracyclines taxanes 64 LHRH receptor positive 64 ZOLINZA 64 midstage clinical 64 stage IIIb 64 sorafenib Nexavar 64 maximally tolerated lipid lowering 64 Sprycel dasatinib 64 refractory systemic ALCL 64 interferon ribavirin 64 Myelodysplastic Syndrome 64 receptor tyrosine kinase inhibitor 64 cetuximab Erbitux R 64 dasatinib Sprycel ® 64 cyclophosphamide chemotherapy 64 trastuzumab Herceptin ® 64 advanced medullary thyroid 64 Azacitidine 64 thalidomide Thalomid 64 FOLFOX6 64 docetaxel Injection Concentrate 64 cell carcinoma RCC 64 Aflibercept 64 gastrointestinal stromal tumor GIST 64 chronic myeloid 64 metastatic renal cell carcinoma 64 refractory indolent NHL 64 MAGE A3 ASCI 64 FUSILEV enhances 64 lymphomas leukemias 64 8mg/kg 64 refractory metastatic colorectal cancer 64 stage IIIb IV 63 Rituxan rituximab 63 galiximab 63 Amgen Neulasta ® 63 Arzerra ofatumumab 63 cisplatin gemcitabine 63 SPRYCEL ® 63 NMIBC 63 Heterozygous Familial Hypercholesterolemia 63 Arranon 63 Pemetrexed 63 Glioblastoma Multiforme 63 Femara letrozole 63 Gemzar gemcitabine 63 adalimumab Humira 63 Acute Myelogenous Leukemia AML 63 Tocilizumab 63 weekly subcutaneous injections 63 Waldenstrom macroglobulinemia 63 Velcade bortezomib 63 demonstrated antitumor activity 63 decompensated liver disease 63 calcineurin inhibitor 63 peginterferon alpha 2a 63 relapsing multiple sclerosis 63 refractory Hodgkin 63 immune thrombocytopenic purpura ITP 63 Gleevec imatinib 63 bone marrow reticulin deposition 63 refractory APL 63 immune thrombocytopenic purpura 63 VELCADE melphalan 63 chronic granulomatous disease 63 cediranib 63 OSI Tarceva 63 ACTEMRA TM 63 Etanercept 63 chemosensitizer 63 exocrine pancreatic insufficiency EPI 63 relapsed CLL 63 metastatic hormone refractory 63 baminercept 63 unresectable tumors 63 Torisel 63 oral rivaroxaban 63 advanced hepatocellular carcinoma 63 Doxil ® 63 docetaxel prednisone 63 fistulizing Crohn disease 63 rufinamide 63 Jevtana 63 idiopathic thrombocytopenic purpura ITP 62 Prednisone Against Refractory 62 #mg ATC 62 Chronic Myelogenous Leukemia CML 62 relapsed multiple myeloma 62 Chronic Myeloid Leukemia 62 generation purine nucleoside 62 Temsirolimus 62 myelodysplastic myeloproliferative diseases 62 metastatic gastric 62 dose escalation clinical 62 indolent follicular non 62 remitting MS 62 Peginterferon 62 nonmetastatic 62 Cutaneous T 62 taxane refractory 62 5 fluorouracil leucovorin 62 evaluating tivozanib 62 TEMODAL 62 Temodar ® 62 rheumatoid arthritis RA psoriatic 62 remission induction 62 lumiliximab 62 CML CP 62 rhabdoid 62 #I TM# 62 Hormone Refractory Prostate Cancer 62 Ph + acute lymphoblastic 62 thetreatment 62 refractory Hodgkin lymphoma 62 Degarelix 62 Decitabine 62 Tanespimycin 62 Amrubicin 62 Nexavar sorafenib 62 fallopian tube carcinoma 62 cyclophosphamide doxorubicin vincristine 62 Relapsed Refractory 62 erlotinib Tarceva ® 62 papillary renal cell carcinoma 62 Meets Primary Endpoint 62 EGFR expressing mCRC 62 Acute Myelogenous Leukemia 62 subcutaneous methylnaltrexone 62 TTF Therapy 62 Plaquenil 62 metastatic kidney 62 Bevacizumab Avastin 62 multiple myeloma MM 62 Romidepsin 62 stage IIIB 62 INSPIRE Trial Phase III 62 aflibercept VEGF Trap 62 refractory ovarian cancer 62 Herceptin trastuzumab 62 Mantle Cell Lymphoma 62 Sudhir Agrawal D.Phil 62 leukemia ALL 62 acute myeloid 62 rituximab refractory 62 recurrent GBM 62 humanised monoclonal antibody 62 deletion 5q 62 oropharyngeal candidiasis OPC 62 phase III isavuconazole 62 steroid refractory ulcerative 62 Flu Cy 62 Vidaza azacitidine 62 capecitabine Xeloda 62 prostate carcinoma 62 cytotoxic therapy 62 naïve HCV 62 GRN# 62 plus prednisone prednisolone 62 metastatic colorectal carcinoma 62 vinorelbine tartrate 62 Certolizumab pegol 62 keloid scarring 62 cell lymphoma CTCL 62 lenalidomide Revlimid R 62 Cariprazine 61 non hodgkin lymphoma 61 refractory metastatic 61 diabetic neuropathic pain 61 unresectable recurrent 61 riociguat 61 paclitaxel cisplatin 61 dacarbazine DTIC 61 Ribavirin causes 61 sunitinib Sutent 61 Gleevec resistant 61 Acute Myeloid Leukaemia AML 61 advanced metastatic renal 61 metastatic bladder 61 undergoing hematopoietic stem 61 estramustine 61 pegylated interferon peg IFN 61 ribavirin RBV 61 OMP #R# 61 Tarceva TM 61 metastatic renal 61 Eculizumab 61 alvespimycin 61 LymphoStat B belimumab 61 class mGluR5 inhibitor 61 carcinoma mCRC 61 pediatric acute lymphoblastic 61 chemoradiation therapy 61 overactive bladder syndrome 61 KRN# 61 idarubicin 61 Pegloticase 61 unresectable stage 61 Onrigin 61 sitaxsentan 61 taxane chemotherapy 61 Stage IIB 61 docetaxel chemotherapy 61 opioid induced constipation OIC 61 Gliadel Wafer 61 lymphocytic leukemia 61 PEGINTRON TM 61 anthracycline containing 61 TO AVOID PREGNANCY WHILE 61 BARACLUDE ® 61 untreated metastatic colorectal 61 trastuzumab Herceptin R 61 rituximab Rituxan 61 HeFH 61 refractory HL 61 gastrointestinal stromal tumors GIST 61 Myelofibrosis 61 Soft Tissue Sarcoma 61 resistant hormone refractory 61 Revlimid lenalidomide 61 oral clodronate 61 cutaneous T 61 lintuzumab SGN 61 lymphoma CTCL 61 mg administered orally 61 antiretroviral naïve 61 bortezomib Velcade 61 LymphoStat B TM 61 Combination REOLYSIN R 61 induced anemia 61 Abrupt discontinuation 61 post herpetic neuralgia PHN 61 selective modulator 61 heavily pretreated 61 refractory follicular lymphoma 61 Naive Patients 61 Aviptadil 61 atypical hemolytic uremic syndrome 61 Cell Lymphoma CTCL 61 atypical Hemolytic Uremic Syndrome 61 DEB# 61 Gemzar ® 61 PNP inhibitor 61 diabetic gastroparesis 61 Infusion reactions 61 ZACTIMA 61 metastatic malignant melanoma 61 Nexavar tablets 61 arthritis PsA 61 non metastatic osteosarcoma 61 Selective Internal 61 Tasigna nilotinib 61 irinotecan containing 61 acute promyelocytic leukemia APL 61 ER CHOP 61 subependymal giant cell 61 cisplatin chemotherapy 61 plus prednisone 61 Cloretazine ® 61 Cannabinor 61 PF # [002] 61 somatostatin analog 61 mecasermin 61 5 FU leucovorin 61 ALN VSP Phase 61 imatinib Gleevec ® 61 Safinamide 61 recurrent NSCLC 61 Tocosol Paclitaxel 61 Atypical Hemolytic Uremic Syndrome 61 relapsed Acute Myeloid 61 PEGylated Fab fragment 61 HERCEPTIN 61 antibody MAb 61 acute lymphoblastic 61 Xeloda ® 61 E1 INT TM 61 propranolol Inderal 61 agalsidase alfa 61 advanced carcinoid 61 TASKi3 60 Acute Myeloid Leukaemia 60 Folfox 60 adjuvant cisplatin 60 Patients Treated With 60 visilizumab 60 Adjuvant chemotherapy 60 IV metastatic melanoma 60 Iressa gefitinib 60 clomipramine 60 Sapacitabine 60 CHOP chemotherapy 60 Kantarjian 60 gastrointestinal stromal tumors 60 IV malignant melanoma 60 previously untreated follicular 60 mRCC 60 follicular Non Hodgkin 60 B Cell Lymphoma 60 gemcitabine carboplatin 60 metastatic renal cell 60 advanced HER2 positive 60 CLARITY study 60 haematologic 60 irinotecan chemotherapy 60 MELAS 60 IV melanoma 60 steroid refractory GvHD 60 non resectable metastatic 60 Brentuximab Vedotin SGN 60 Aptivus ® 60 Kit CD# positive 60 alpha 2a 60 Bendamustine 60 recurrent herpes labialis 60 treating neuropathic pain 60 chronic idiopathic thrombocytopenic purpura 60 R abatacept 60 PEG IFN 60 advanced epithelial ovarian 60 metastatic sarcoma 60 Zavesca r 60 lymphoma leukemia 60 relapsed 60 mapatumumab 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 Dementia Related Psychosis 60 recurrent metastatic 60 cardiotoxic 60 haematological cancers 60 benign prostatic hypertrophy BPH 60 pegylated liposomal doxorubicin 60 Complicated Skin 60 #mg BID [001] 60 vandetanib 60 HuMax EGFr 60 Pfizer Sutent 60 TNF Tumor Necrosis Factor 60 Pivotal Phase III 60 colorectal cancer liver metastases 60 GW# [003] 60 Irinotecan 60 gemcitabine Gemzar ® 60 Hepatocellular Carcinoma HCC 60 rheumatoid arthritis psoriatic arthritis 60 PKC# 60 novel VDA molecule 60 cyclophosphamide FC 60 autoantibody positive 60 metaglidasen 60 Relapsed Refractory Multiple Myeloma 60 invasive candidiasis 60 dasatinib Sprycel 60 Eltrombopag 60 infliximab monotherapy 60 chronic ITP patients 60 hypercholesterolemic patients 60 Laquinimod 60 Mg Uk 60 AA Amyloidosis 60 IV NSCLC 60 oxypurinol 60 symptomatic BPH 60 Oxaliplatin 60 Natalizumab 60 mitoxantrone chemotherapy 60 bortezomib Velcade R 60 hyperphenylalaninemia HPA due 60 refractory SCLC 60 weekly intravenous infusions 60 superficial bladder cancer 60 gefitinib Iressa 60 medically refractory 60 tuberous sclerosis TS 60 Fluorouracil 60 uremic pruritus 60 Anti VEGF 60 HER2 positive metastatic breast 60 radiation chemoradiation 60 EOquin TM phase 60 relapsed refractory 60 Adjunctive 60 alfa 2a 60 eosinophilic asthma 60 perioperatively 60 Fingolimod 60 Initiate Phase 60 opioid naive 60 BCG refractory carcinoma 60 Hsp# Inhibitor 60 5-fluorouracil/leucovorin 60 relapsing remitting multiple sclerosis 60 cetuximab Erbitux 60 everolimus tablets 60 intravenous cyclophosphamide 60 ELACYT 60 Acute Myeloid Leukemia AML 60 YONDELIS 60 abatacept Orencia 60 forodesine 60 T Cell Lymphoma 60 intravenous RSD# 60 Gleevec imatinib mesylate 60 SNT MC# 60 Alequel 60 pseudobulbar affect PBA 60 Aryplase 60 catheter occlusion 60 esophageal candidiasis 60 neurologic progression 60 leukemia CML 60 alkylating agent 60 subcutaneous enoxaparin 60 primary hypercholesterolemia 60 PEGylated anti 60 Navelbine ® 60 prokinetic agent 60 Darinaparsin 60 refractory ALCL 60 denileukin diftitox 60 mildly symptomatic 60 operable breast cancer 60 phase IIb study 60 Imuran 60 neurogenic bladder 60 dextromethorphan quinidine 60 bortezomib refractory 60 Proxinium TM 60 Pegylated Interferon 60 EGFR mutation positive 60 Zarnestra 60 radiation sensitizer 60 ixabepilone 60 steroid refractory 60 hormone LHRH antagonist 60 Omnitarg 59 RECORD1 59 dual endothelin receptor antagonist 59 FOLFOX4 59 Relapsing Multiple Sclerosis 59 Riluzole 59 Seliciclib 59 induce orthostatic hypotension 59 untreated chronic lymphocytic 59 candesartan cilexetil 59 Bezielle 59 smoldering multiple myeloma 59 Ophena TM 59 Cloretazine 59 alpha1 antitrypsin deficiency 59 KRAS mutant tumors 59 docetaxel Taxotere ® 59 SYN# 59 resectable pancreatic cancer 59 fluorouracil leucovorin 59 either acutely decompensated 59 patients receiving myelosuppressive 59 pegylated interferon alpha 59 Initiates Phase III 59 relapsed myeloma 59 Paraplatin ® 59 abacavir lamivudine 59 refractory PTCL 59 Vidaza ® 59 pediatric malignancies 59 smoldering myeloma 59 dexamethasone Decadron 59 Investigational Treatment 59 IMiDs ® 59 Toxicities 59 cilengitide 59 Paxil paroxetine 59 Everolimus 59 alefacept 59 treatment naïve genotype 59 Hodgkin lymphoma HL 59 trastuzumab DM1 59 evaluating picoplatin 59 virus HCV protease inhibitor 59 Tyrima 59 CTAP# Capsules 59 Golimumab 59 sorafenib tablets 59 nutlin 3a 59 refractory acute lymphoblastic 59 Silodosin 59 Malignant Glioma 59 allogeneic HSCT 59 Mipomersen 59 adefovir dipivoxil 59 Romiplostim 59 myelofibrosis MF 59 Mepact 59 immunomodulatory agents 59 IL# PE#QQR 59 Amgen Neulasta R 59 elacytarabine 59 budesonide foam 59 etanercept Enbrel 59 Panzem R NCD 59 pneumocystis carinii pneumonia 59 novel emulsion formulation 59 severe oral mucositis 59 untreated multiple myeloma 59 chemotherapy fludarabine 59 CLL SLL 59 plus dexamethasone 59 epirubicin cyclophosphamide 59 benign prostatic hypertrophy 59 Severe Sepsis 59 palifermin 59 Novartis Afinitor 59 Vandetanib 59 OHR/AVR# 59 oxaliplatin Eloxatin 59 Major Depressive Disorder MDD 59 taxane resistant 59 paclitaxel poliglumex 59 Xelox 59 bladder ovarian 59 antiestrogen therapy 59 dose escalation phase 59 Intervention Effectiveness 59 neoadjuvant treatment 59 Topotecan 59 castration resistant hormone refractory 59 rALLy clinical trial 59 SNT-MC#/idebenone 59 cetuximab Erbitux ® 59 including eniluracil ADH 59 RCW breast cancer 59 deep venous thromboses 59 bacillus Calmette Guerin BCG 59 inoperable pancreatic cancer 59 stage chemoresistant ovarian 59 RRMS patients 59 Paroxysmal Nocturnal Hemoglobinuria PNH 59 Li Fraumeni Syndrome 59 Erlotinib 59 hepatic metastases 59 Capesaris 59 Elotuzumab 59 Dacogen injection 59 Randomized Phase II 59 Initiates Enrollment 59 refractory gastrointestinal stromal 59 fludarabine phosphate 59 bendamustine 59 Cancer Patients Treated 59 ThermoDox R 59 liposomal amphotericin B 59 small molecule Hedgehog 59 Philadelphia Chromosome Positive 59 sedative pentobarbital sodium 59 doxorubicin cyclophosphamide 59 sulfonylurea metformin 59 Noxafil 59 Mabthera 59 R lenalidomide 59 pancreatic neuroendocrine tumors 59 biochemical relapse 59 paroxysmal nocturnal hemoglobinuria PNH 59 chronic thromboembolic pulmonary 59 antiangiogenic therapy 59 SUPPRELIN R LA 59 ara C 59 Chronic Lymphocytic Leukemia 59 Insegia 59 vinflunine 59 Aplidin 59 pomalidomide 59 goserelin 59 peritoneal cancer 59 chemotherapy docetaxel 59 splenectomized 59 Follicular Lymphoma 59 metastatic pancreatic 59 Albuferon TM 59 monoclonal antibody conjugated 59 prostate cancer CRPC 59 Advaxis Phase 59 Bortezomib 59 Crizotinib 59 Adjuvant therapy 59 RoACTEMRA 59 oral vancomycin 59 Cyclophosphamide 59 antiretroviral naive 59 p#HER# positive 59 registrational Phase 59 Proellex TM 59 randomized Phase IIb 59 diagnosed glioblastoma multiforme 59 GSK# [002] 59 metastatic castration resistant 59 potent triglyceride lowering 59 amisulpride 59 Pazopanib 59 anagrelide 59 systemic juvenile idiopathic 59 FOLFOX chemotherapy 59 oral ridaforolimus 59 painful diabetic neuropathy 59 nilotinib Tasigna ® 59 adult chronic ITP 59 mycosis fungoides 59 metastatic ovarian cancer 59 Acute Myeloid Leukemia 59 CD# antibody [002] 59 Darusentan 59 Genasense ® 59 4mg/kg 59 Omacetaxine 59 EOquin TM 59 Abatacept 59 regorafenib 59 mycophenolic acid 59 acyclovir Lauriad R 59 metastatic dermatofibrosarcoma protuberans DFSP 59 Sutent sunitinib 59 Abilify aripiprazole 59 receiving XGEVA 59 decompensated cirrhosis 59 non constipating irritable 59 R sorafenib tablets 59 Nilotinib 59 Fulvestrant 59 oral prodrug 59 intravenous belinostat 59 HCV RESPOND 2 59 colorectal liver metastases 58 tafamidis 58 gemcitabine chemotherapy 58 Randomized Phase 58 omacetaxine mepesuccinate 58 trabectedin 58 Subgroup analysis 58 hPAM4 58 unresectable liver cancer 58 postoperative chemotherapy 58 Diffuse Large B 58 AKT inhibitor 58 Fx #A 58 localized renal 58 systemic mastocytosis 58 induce remission 58 Ceflatonin 58 whose tumors overexpress 58 Triapine R 58 phase IIb III 58 imexon 58 EGFR TKI 58 constipation predominant irritable bowel 58 severe hypercholesterolemia 58 taxotere 58 allogeneic hematopoietic stem cell 58 Fludarabine 58 aripiprazole Abilify 58 treatment naive genotype 58 FOLFIRI alone 58 axitinib 58 metastatic carcinoid 58 Neoadjuvant 58 Daclizumab 58 Phase IIA 58 ropinirole Requip 58 EndoTAGTM 1 58 Roche Xeloda 58 Hodgkin lymphoma NHL 58 efalizumab 58 conventional DMARDs 58 via intradermal injections 58 HIV HCV coinfected 58 Combination therapy 58 Simulect 58 oropharyngeal candidiasis 58 Bi Polar Disorder 58 Phase 2b Clinical Trial 58 TM pralatrexate injection 58 hypereosinophilic syndrome 58 combining voreloxin 58 humanized therapeutic 58 placebo dexamethasone 58 mGluR5 NAM 58 Vicinium TM 58 gemtuzumab ozogamicin 58 Belldegrun 58 acute myelogenous leukemia AML 58 receiving chemoradiation therapy 58 ankylosing spondylitis AS 58 acute promyelocytic leukemia 58 Patients Receiving 58 reduce serum phosphate 58 MGd 58 folinic acid 58 PLX MS 58 hA# 58 nucleoside analog 58 peginterferon ribavirin 58 omega interferon 58 C1 INH deficiency 58 5-FU/LV 58 non myeloid malignancies 58 pamidronate 58 Enzastaurin 58 Antitumor Activity 58 Alessandro Riva 58 Teriflunomide 58 receiving highly emetogenic 58 visceral metastases 58 taxane therapy 58 oral deforolimus 58 FOLFOX6 chemotherapy regimen 58 Zenvia ™ 58 CTAP# 58 acute HAE attacks 58 Evoltra ® 58 chronic eosinophilic leukemia 58 HCV IET 58 selective phosphodiesterase 58 Tipranavir 58 hoFH 58 Chronic Lymphocytic Leukemia CLL 58 Taxotere docetaxel 58 bevacizumab Avastin ® 58 relapsed SCLC 58 refractory chronic myeloid 58 investigational monoclonal antibody 58 pouchitis 58 herpetic keratitis 58 untreated metastatic pancreatic 58 VBLOC TM vagal blocking 58 Lenalidomide 58 Chronic Myelogenous Leukemia 58 Acute Leukemia 58 precancerous condition 58 huN# DM1 58 complement inhibitor eculizumab 58 temozolomide Temodar 58 Paraplatin ® carboplatin 58 randomized multicenter trial 58 EGFR expressing 58 Completes Patient Enrollment 58 minimally symptomatic 58 azacitidine 58 systemic ALCL patients 58 orally inhaled migraine 58 generalized anxiety disorder GAD 58 daily subcutaneous injections 58 dexanabinol 58 oral JAK#/JAK# inhibitor 58 bladder carcinoma 58 piperacillin tazobactam 58 oral chemotherapeutic agent 58 Neovascular Age Related Macular 58 Tramiprosate ALZHEMED TM 58 idiopathic thrombocytopenic purpura 58 MS spasticity 58 fallopian tube cancers 58 pertuzumab 58 Pirfenidone 58 ELOXATIN 58 relapsed mantle 58 T1c 58 peritoneal carcinomatosis 58 lymphoid malignancies 58 Previously Treated 58 rALLy 58 demethylating agents 58 docetaxel Taxotere R 58 adjunctive placebo 58 blastic phase 58 oral anti arrhythmic 58 pregabalin Lyrica 58 hereditary deficiency 58 Gleevec Glivec 58 naive HCV 58 Cloretazine R 58 known sulfonamide allergy 58 basal cell carcinoma BCC 58 EGFR tyrosine kinase inhibitor 58 PEGylated interferon beta 1a 58 mCRC patients 58 palliative radiotherapy 58 Tectin TM 58 inhaled liposomal ciprofloxacin 58 BRAF V#E mutation 58 polycythemia vera essential thrombocythemia 58 Carbamazepine 58 Oxypurinol 58 Toremifene 58 non resectable 58 mesylate 58 Raptiva ® 58 Neuvenge 58 evaluating T DM1 58 Stage IIIB IV 58 Clolar ® 58 telaprevir dosed 58 aliskiren amlodipine 58 Linagliptin 58 Relapsing Remitting Multiple Sclerosis 58 pan HDAC inhibitor 58 detectable HCV RNA 58 phase IIa 58 Bcr Abl T#I mutation 58 heavily pretreated patients 58 tenofovir emtricitabine 58 epoetin beta 58 neutropenic sepsis 58 unresectable Stage III 58 acute myelogenous 58 Anthracycline 58 radiotherapy RT 58 allogeneic bone marrow 58 Orally administered 58 clazosentan 58 relapsed ALL 58 essential thrombocythemia ET 58 postherpetic neuralgia PHN 58 chemoradiotherapy 58 Syndrome LEMS 58 radiolabeled TM# 58 sodium stibogluconate 58 Lamotrigine 58 TORISEL 58 rFVIIa 58 RhuDex TM 58 ORENCIA ® 58 immunosuppressant drug 58 HBeAg negative 58 Merck KGaA Erbitux 58 Metastatic Melanoma 58 Campath alemtuzumab 58 RLAI 58 Severe Primary IGFD 58 Fluvastatin 58 zoledronate 58 flutamide 58 epirubicin 58 BRIM3 58 ADAGEN 58 primary immunodeficiency PI 58 RhuDex ® 58 haloperidol Haldol 58 PROCRIT ® 58 Mitoxantrone 58 Helicobacter pylori eradication 58 phase IIb clinical 58 CINQUIL 58 oral methylnaltrexone 58 hepatorenal syndrome 58 HuMax CD4 58 intravesical infusion therapy 58 paricalcitol 58 hepatic encephalopathy HE 58 MIRAPEX ER 58 castration resistant prostate cancer 58 anthracycline chemotherapy 58 q8h 58 Kinoid 58 Pertuzumab 58 homozygous familial hypercholesterolemia 58 metastatic lung cancer 58 PROSTVAC ® 58 dimebon latrepirdine 58 clodronate 58 phase Ib 58 pegylated interferon alfa 58 TAXOTERE ® 58 OvaRex ® MAb 58 delivers fluocinolone acetonide FA 58 Mycophenolate Mofetil 58 Roche Herceptin 58 antirheumatic 58 chemo radiotherapy 58 Gattex 58 Bucindolol 58 Infliximab 58 GOUT 58 opioid tolerant adult 58 chronic rheumatic 58 psoriatic arthritis PsA 58 retinal vein occlusion induced 58 refractory gout 58 INCB# [003] 58 metastatic HRPC 58 transplantation HCT 58 nonalcoholic steatohepatitis NASH 57 cutaneous T cell 57 huC# DM4 57 CIMZIA TM certolizumab pegol 57 HBeAg + 57 relapsed acute myelogenous 57 sorafenib Nexavar ® 57 ralfinamide 57 #mg/m# [002] 57 nucleotide analogue 57 antimetabolite 57 ritonavir boosted 57 superficial basal cell carcinoma 57 Tarceva erlotinib 57 FOLOTYN ® 57 olaparib 57 docetaxel Taxotere 57 Phase #b/#a trial 57 CVP cyclophosphamide vincristine 57 Lubiprostone 57 Tykerb lapatinib 57 transarterial 57 proteasome inhibitor 57 azilsartan medoxomil 57 Copegus ribavirin 57 MabCampath 57 MabThera Rituxan 57 leukemia lymphoma multiple myeloma 57 Myelodysplasia 57 Vicriviroc 57 noninfectious uveitis 57 Zeldox 57 5q deletion 57 AML acute myeloid 57 metastatic androgen independent 57 DFMO 57 choroidal vasculopathy 57 Cloretazine R VNP#M 57 Peg IFN 57 PAOD 57 tocilizumab 57 chronic HCV genotype 57 Capecitabine 57 albiglutide 57 R Saizen R 57 Mg Usa 57 Chronic lymphocytic leukemia 57 zanolimumab 57 achieved ACR# 57 IBS C 57 Akt inhibitor 57 depressive episodes associated 57 adjuvant colon cancer 57 Levoleucovorin 57 Relapsing Remitting MS 57 Leukemia AML 57 IIa trial